GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Natco Pharma Ltd

Natco Pharma Q2 FY27 Consolidated Net Profit at Rs. 2,026 million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 13 Nov 2026, 02:49 PM IST  ·  BSE ID: cb0eeade-da2a-421f-87c4-804bfb446327
View Original BSE Filing (PDF)
💡
In Simple Terms
Natco Pharma announced its Q2 FY27 financial results and declared an interim dividend of Rs. 1.25 per share.
🤖 AI Summary
  • Natco Pharma Ltd reported consolidated net profit of Rs. 2,026 million for the quarter ended September 30, 2026 (Q2 FY27).
  • Consolidated revenue from operations for Q2 FY27 stood at Rs. 9,673 million.
  • The Board declared a second interim dividend of Rs. 1.25 (62.50%) per equity share of Rs. 2/- for FY27.
  • The record date for the second interim dividend is November 19, 2026, with payment commencing November 27, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Consolidated) - Q2 FY27
9,673 million
-29.03
Profit for the period (Consolidated) - Q2 FY27
2,026 million
-60.89
Basic Earnings per share (Consolidated) - Q2 FY27
11.31
-60.99
Total income (Consolidated) - Q2 FY27
10,194 million
-30.32
Second Interim Dividend per share - FY27
1.25
🏢 How This Affects the Company
📈
Business Impact
Consolidated revenue from operations for Q2 FY27 was Rs. 9,673 million. The Pharmaceuticals segment revenue for Q2 FY27 was Rs. 9,061 million, and for the half year ended September 30, 2026, it was Rs. 16,339 million.
💰
Financial Impact
Consolidated profit for the period (net profit) for Q2 FY27 was Rs. 2,026 million. Basic Earnings Per Share (EPS) for the quarter was Rs. 11.31, and for the half year ended September 30, 2026, it was Rs. 22.84.
👥 What This Means For Shareholders
✅
Action Required
Shareholders holding shares on or before the record date of November 19, 2026, will be eligible for the second interim dividend.
👤
Who Is Affected
All shareholders owning equity shares of Natco Pharma Ltd as of November 19, 2026, will receive the Rs. 1.25 per share interim dividend.
🔍
Management Signal
The declaration of a second interim dividend within FY27 signals management's confidence in the company's financial performance and ongoing commitment to shareholder distributions.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Dividend payment date – verify payment to eligible shareholders by November 27, 2026.
Q3 FY27 results – analyze trends in revenue from operations and profit for the period.
Updates on Scheme of Arrangement – monitor changes to the scheme mentioned in the notes.
LOW RISK No new significant risks or negative events were disclosed in the filing.
💡 Investor Takeaway
Natco Pharma Ltd reported a consolidated net profit of Rs. 2,026 million for Q2 FY27. The Board declared a second interim dividend of Rs. 1.25 per equity share for FY27. This dividend has a record date of November 19, 2026, with payments starting November 27, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Reported consolidated profit for the period of Rs. 2,026 million for Q2 FY27, compared to Rs. 1,222 million in Q1 FY27.
  • Total comprehensive income for Q2 FY27 was Rs. 2,531 million, showing an increase from Rs. 5,583 million in Q2 FY26.

⚠️ Concerns

  • Consolidated revenue from operations for Q2 FY27 was Rs. 9,673 million, down from Rs. 13,630 million in Q2 FY26.
  • Consolidated profit before tax for Q2 FY27 was Rs. 2,432 million, lower than Rs. 6,137 million in Q2 FY26.
📅 Company Track Record
Natco Pharma Ltd previously announced its Board meeting on August 14, 2026, for Q1 FY27 results and an interim dividend. The company also reported a Scheme of Arrangement approved by the Board on March 24, 2026, to transfer its Agrochemicals division.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Natco Pharma's consolidated net profit for Q2 FY27?
Natco Pharma's consolidated profit for the period (net profit) for the quarter ended September 30, 2026 (Q2 FY27) was Rs. 2,026 million.
What interim dividend did Natco Pharma declare for FY27?
Natco Pharma declared a second interim dividend of Rs. 1.25 per equity share (62.50%) of Rs. 2/- each for the financial year 2026-27.
What is the record date for Natco Pharma's second interim dividend?
The record date for determining eligible shareholders for the second interim dividend is fixed as Thursday, November 19, 2026.
When will Natco Pharma pay the declared interim dividend?
The payment of the second interim dividend will commence from November 27, 2026.
What was Natco Pharma's consolidated revenue from operations for Q2 FY27?
Natco Pharma's consolidated revenue from operations for the quarter ended September 30, 2026 (Q2 FY27) was Rs. 9,673 million.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.